QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
LON:INS

Instem (INS) Share Price, News & Analysis

GBX 830
0.00 (0.00%)
(As of 11/20/2023)
Today's Range
830
830
50-Day Range
830
830
52-Week Range
580
835.56
Volume
3,800 shs
Average Volume
85,542 shs
Market Capitalization
£199.62 million
P/E Ratio
5,928.57
Dividend Yield
N/A
Price Target
N/A
INS stock logo

About Instem Stock (LON:INS)

Instem plc, together with its subsidiaries, provides information technology solutions and services to the life sciences healthcare market worldwide. The company offers solutions for data collection, management, and analysis to meet the needs of life science and healthcare organizations for data-driven decision making. Its solutions include ALPHADAS, an eSource system for early phase clinical trials; BioRails for discovery data management; Comet Assay IV, a live video imaging system for reproducible comet slide scoring; and Cyto Study Manager, a data acquisition and reporting solution. The company also offers computational toxicology products and services; Blur Clinical Annonymization; Logbook ELN, a repository for information; Morphit for discovery data visualization; NOTOCORD-hem software platforms to acquire, display, and analyze physiological signals; and Provantis, a windows-based system for non-clinical evaluation studies. In addition, it provides Samarind RMS to manage medical product information; submit platform that offers tools and services for the creation and management of SEND datasets and associated documents for contract research organizations and sponsors; SENDView, an application that simplifies the review of SEND datasets; KnowledgeScan Target Safety Assessment services; SENDTrial, a web based solution that can be accessed through a subscription; and Predict delivers computational models. Further, the company provides Sorcerer Colony Counter; sales and administrative support; training, validation, consultancy, cloud, and safety assessment and regulatory information management software services; software solutions to extract intelligence from research and development related healthcare data; and holds intellectual property rights and investment. It also develops, manufactures, and supplies software and hardware products for in vitro study data collection and management. Instem plc was founded in 1969 and is headquartered in Stone, the United Kingdom.

INS Stock Price History

INS Stock News Headlines

The Wrap: Maternal healthcare
Crypto Market Preps For Trillions Worth of Inflows!
Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.
Austin tech companies made 20 key hires in January
CDISC Names Chris Decker President and CEO
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Culture, Tradition, STEM and Learning on the Land
Takeover deal undervalues Instem, says big investor
Instem Swung to 1H Pretax Loss Amid Higher Costs
Instem board ‘absurd’ to back £203m bid
ALEX BRUMMER: Investors who shunned UK
Samson Rock Capital LLP - Re-issue: Form 8.3 - Instem Plc
See More Headlines
Receive INS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Instem and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Health Information Services
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
500
Year Founded
N/A

Profitability

Net Income
£3.34 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£61.63 million
Cash Flow
GBX 54.41 per share
Book Value
GBX 239 per share

Miscellaneous

Free Float
N/A
Market Cap
£199.62 million
Optionable
Not Optionable
Beta
0.42
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Phil J. Reason (Age 61)
    CEO & Executive Director
    Comp: $300k
  • Mr. Nigel John Goldsmith (Age 61)
    CFO, Secretary & Executive Director
    Comp: $166k
  • Ms. Marybeth Thompson
    Chief Operating Officer
  • Dr. Gordon Smith Baxter
    Chief Scientific Officer
  • Mr. Mark Poggi M.B.A.
    Ph.D., Executive Vice President of Global Sales
  • Ms. Eve Leconte
    Chief People & Culture Officer
  • Mr. Mike Harwood
    Chief Product Officer
  • Mr. Gregor Grant
    Executive Vice President of Preclinical Solutions
  • Mr. John Leveille
    Executive Vice President of Clinical Trial Acceleration

INS Stock Analysis - Frequently Asked Questions

How have INS shares performed in 2024?

Instem's stock was trading at GBX 830 at the start of the year. Since then, INS shares have increased by 0.0% and is now trading at GBX 830.
View the best growth stocks for 2024 here
.

What other stocks do shareholders of Instem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Instem investors own include Abeona Therapeutics (ABEO), ARCA biopharma (ABIO), Apollo Investment (AINV), Alico (ALCO), Corindus Vascular Robotics (CVRS), DSS (DSS), Evans Bancorp (EVBN), The LGL Group (LGL) and UQM Technologies (UQM).

How do I buy shares of Instem?

Shares of INS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:INS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners